Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

309 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Atezolizumab plus bevacizumab in advanced Merkel cell carcinoma: A prospective study.
de Sousa LG, Liu S, Bhosale P, Altan M, Darbonne W, Schulze K, Dervin S, Yun C, Mahvash A, Verma A, Futreal A, Gite S, Cuentas EP, Cho WC, Wistuba I, Yao JC, Woodman SE, Halperin DM, Ferrarotto R. de Sousa LG, et al. Among authors: yao jc. Oral Oncol. 2024 Apr;151:106747. doi: 10.1016/j.oraloncology.2024.106747. Epub 2024 Mar 8. Oral Oncol. 2024. PMID: 38460288 No abstract available.
Characterization of serum estradiol level and tissue estrogen receptor immunostaining with clinical response and reproductive factor changes in Chinese female patients with esophageal squamous cell carcinoma.
Zhang D, Ku J, Liu R, Wu H, Liang G, Wei Y, Chen P, Zhao X, Liu S, Li Y, Yao J, Song X, Wang L. Zhang D, et al. Biomed Pharmacother. 2017 Sep;93:879-884. doi: 10.1016/j.biopha.2017.07.020. Epub 2017 Jul 14. Biomed Pharmacother. 2017. PMID: 28724213
Circulating tumor DNA (ctDNA) as a biomarker of response to therapy in advanced Hepatocellular carcinoma treated with Nivolumab.
Mohamed YI, Lee SS, Demir T, Chamseddine S, Hu ZI, Xiao L, Elsayes K, Morris JS, Wolff RA, Hiatia R, Qayyum A, Rashid A, Duda DG, Yao JC, LaPelusa M, Koay EJ, Mahvash A, Al Azzam A, Dumbrava EE, Hassan M, Amin HM, Kaseb AO. Mohamed YI, et al. Among authors: yao jc. Cancer Biomark. 2024;41(1):83-91. doi: 10.3233/CBM-230431. Cancer Biomark. 2024. PMID: 39269823
Gefitinib (an EGFR tyrosine kinase inhibitor) plus anlotinib (an multikinase inhibitor) for untreated, EGFR-mutated, advanced non-small cell lung cancer (FL-ALTER): a multicenter phase III trial.
Zhou HQ, Zhang YX, Chen G, Yu QT, Zhang H, Wu GW, Wu D, Lin YC, Zhu JF, Chen JH, Hu XH, Lan B, Zhou ZQ, Lin HF, Wang ZB, Lei XL, Pan SM, Chen LM, Zhang J, Kong TD, Yao JC, Zheng X, Li F, Zhang L, Fang WF. Zhou HQ, et al. Among authors: yao jc. Signal Transduct Target Ther. 2024 Aug 13;9(1):215. doi: 10.1038/s41392-024-01927-9. Signal Transduct Target Ther. 2024. PMID: 39134529 Free PMC article. Clinical Trial.
Chemotherapy Plus Atezolizumab Pre- and Post-Resection in Localized Esophageal or Gastroesophageal Junction Adenocarcinomas: A Phase I/II Single-Arm Study.
Sewastjanow-Silva M, Xiao L, Gonzalez GN, Wang X, Hofstetter W, Swisher S, Mehran R, Sepesi B, Bhutani MS, Weston B, Coronel E, Waters RE, Rogers JE, Smith J, Lyons L, Reilly N, Yao JC, Ajani JA, Murphy MB. Sewastjanow-Silva M, et al. Among authors: yao jc. Cancers (Basel). 2024 Mar 31;16(7):1378. doi: 10.3390/cancers16071378. Cancers (Basel). 2024. PMID: 38611056 Free PMC article.
309 results